Please assess the completion status of the following clinical trial:

Trial Title: Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Performance status ≤1~* Age ≥18 years and ≤ 75 years old~* Histologically-confirmed adenocarcinoma of the prostate~* Treated with continuous androgen ablative therapy (either surgical castration or LHRH agonist/antagonist) with documented castrate level of serum testosterone (\<50 ng/dl)~* Metastatic disease radiographically documented by CT or bone scan~* Patient must be HLA typed at high resolution using DNA based typing at the following loci: HLA-A, -B, -C, and DRB1~* Patient must have available one or more potential first (biologic mother, sister, half-sister, or daughter) or second-degree related female donor. Mothers and daughters have a 100% chance of being haploidentical matches, sisters a 75% chance of being matched or haploidentical, and second degree relatives have a 50% chance of being haploidentical matches. The donor and recipient must be HLA identical for at least one antigen at HLA-A, -B, -C and HLA-DRB1.~* Screening PSA must be ≥ 1.0 ng/mL.~* Prior therapy with one second line hormonal therapy is allowed (i.e. bicalutamide, nilutamide, flutamide, ketoconazole, abiraterone, enzalutamide, ARN-509).~* Prior docetaxel (≤ 6 cycles) as first line therapy~* Cardiac ejection fraction at rest must be ≥ 40%~* Acceptable liver function: Bilirubin \< 2.5 mg/dL (unless due to Gilbert's disease, AST (SGOT) and ALT (SGPT) \< 5 times upper limit of normal.~* Acceptable renal function: Serum creatinine within normal range.~* Pulmonary function: DLCO (corrected for hemoglobin), FEV1 and FVC \>50% predicted.~* At least 4 wks since prior radiation or surgery with full recovery (no persistent toxicity ≥ Grade 1)~* Ability to understand and willingness to sign a written informed consent document.~Exclusion Criteria:~* Prior treatment with Sipuleucel-T, radium-223, strontium-89, or samarium-153~* Prior chemotherapy (docetaxel, cabazitaxel) for castrate resistant prostate cancer~* Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study~* Active uncontrolled infection, including known history of HIV/AIDS or hepatitis B or C.~* Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bone marrow transplantation (Type: EXPERIMENTAL): Bone marrow transplantation followed by Cytoxan and testosterone~Day -6 to -1: Subjects will be treated with a standard non-myeloablative conditioning regimen~Day 0: subjects will be infused with non-T-cell depleted bone marrow from a related female donor.~Subjects will receive GVHD prophylaxis consisting of:~Day +3 and +4: Cytoxan (Cy) 50mg/kg IV Day +5 through Day +180: tacrolimus (IV or PO) beginning \[dose adjusted to maintain trough level of 5-15 ng/mL\] Day +5 through Day +35: Mycophenolate mofetil (MMF) 15 mg/kg PO TID, with a maximum dose of 1g TID.~Day +5: filgrastim (G-CSF) 5 mcg/kg/day, continued until ANC ≥ 1500/mm3.~Day +60, +90, and +120: testosterone cypionate 400 mg IM every 30 days x 3 doses~Subjects will be maintained on continuous LHRH agonist/antagonist therapy (if not previously surgically castrated). Subjects who achieve biochemical CR will stop LHRH agonist/antagonist treatmentat day 180.

Based on this trial design, predict the completion outcome and termination type (if applicable).